Lovastatin contraindications: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Lovastatin}} {{CMG}}; {{AE}} {{SS}} ==Contraindications== The use of Altoprev® is contraindicated in the following conditions: *Concomitant administration of st..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Contraindications== | ==Contraindications== | ||
The use of Altoprev® is contraindicated in the following conditions: | The use of Altoprev® is contraindicated in the following conditions: | ||
*Concomitant administration of strong CYP3A inhibitors [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)]. | *Concomitant administration of strong CYP3A inhibitors [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)]. | ||
*Concomitant administration of erythromycin [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)]. | *Concomitant administration of [[erythromycin]] [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)]. | ||
*Hypersensitivity to any component of this product [see Adverse Reactions (6.1)]. Active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels [see Warnings and Precautions, Liver Enzyme Abnormalities (5.2)]. | *[[Hypersensitivity]] to any component of this product [see Adverse Reactions (6.1)]. Active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels [see Warnings and Precautions, Liver Enzyme Abnormalities (5.2)]. | ||
*Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Altoprev® may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see Use in Specific Populations (8.1) | *Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease [[cholesterol]] synthesis and possibly the synthesis of other biologically active substances derived from [[cholesterol]], Altoprev® may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)]. | ||
*Nursing mothers. Because another drug in this class passes into breast milk, and because HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require Altoprev® treatment should be advised not to nurse their infants. [see Use in Specific Populations (8.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | *Nursing mothers. Because another drug in this class passes into breast milk, and because [[HMG-CoA]] reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require Altoprev® treatment should be advised not to nurse their infants. [see Use in Specific Populations (8.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 00:49, 14 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
The use of Altoprev® is contraindicated in the following conditions:
- Concomitant administration of strong CYP3A inhibitors [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)].
- Concomitant administration of erythromycin [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)].
- Hypersensitivity to any component of this product [see Adverse Reactions (6.1)]. Active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels [see Warnings and Precautions, Liver Enzyme Abnormalities (5.2)].
- Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Altoprev® may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)].
- Nursing mothers. Because another drug in this class passes into breast milk, and because HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require Altoprev® treatment should be advised not to nurse their infants. [see Use in Specific Populations (8.3)].[1]
References
- ↑ "ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.]". Retrieved 13 February 2014.